Latest Industry Insights

In this interview, Technology Networks spoke with Dr Dena Marrinucci, Truvian chief operating officer and co-founder, to learn more about the limitations of the current blood testing process and the role of point-of-care blood testing in driving healthier outcomes.

In this industry insights piece, we explore how gene therapies represent a rapidly growing new paradigm — both therapeutically and with respect to how they are managed within the larger scope of healthcare — and how this has wide-ranging impacts on several key areas, including regulation.

Arquer Diagnostics is developing non-invasive tests for diagnosing and monitoring cancer, using patented technology to detect the cancer biomarker MCM5. Technology Networks had the pleasure of speaking with Nadia Whittley, Chief Executive Officer of Arquer Diagnostics, to learn more about the study and its significance.

To learn more about the ways that antibody tests are being used in the pandemic, Technology Networks spoke to Heather-Read Harper, European Senior Manager for Immunoassay and Clinical Chemistry at Beckman Coulter.

Today, plant alkaloids are attracting notice as novel therapies for conditions involving inflammation, such as metabolic syndrome, autoimmune disease and even for aging, which are often characterized by chronic, low-grade over-activation of the immune system. This piece takes a closer look at the need for novel treatments and the best uses for plant alkaloids.

Technology Networks spoke with Dr Jan Hellemans, CTO and co-founder of CRO Biogazelle, as well as co-author of the MIQE guidelines, to learn why PCR-based technologies are the "workhorse" technologies for the company.

Verve Therapeutics is utilizing two of the biggest scientific breakthroughs of the twenty-first century – DNA sequencing and genome editing – to design a one-time treatment for lowering cholesterol.

The emergence of SARS-CoV-2 variants has led to concerns over the potential impacts there could be on the effectiveness of diagnostics and other countermeasures. Here, we look at the effects the B.1.1.7 variant may have on diagnostic tests.

Technology Networks recently had the pleasure of speaking with Sam Cooper, CEO and co-founder of Phenomic AI. Cooper discusses how the company is leveraging advanced machine learning techniques to interrogate cell–cell interactions responsible for driving many disease mechanisms.

2020 was an important year for proteomics. The COVID-19 global pandemic cast a spotlight on the field's clinical utility in the fight against a public health crisis, from which there are many lessons to be drawn that will undoubtedly influence the landscape of the field for years to come. Technology Networks spoke with Rohan Thakur, executive vice president of Life Sciences Mass Spectrometry at Bruker Daltonics, to discuss the current state-of-play in proteomics.